Last reviewed · How we verify
Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.
Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets. is a Small molecule drug developed by Tongji Hospital. It is currently FDA-approved.
At a glance
| Generic name | Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets. |
|---|---|
| Sponsor | Tongji Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets. CI brief — competitive landscape report
- Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets. updates RSS · CI watch RSS
- Tongji Hospital portfolio CI
Frequently asked questions about Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.
What is Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.?
Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets. is a Small molecule drug developed by Tongji Hospital.
Who makes Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.?
Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets. is developed and marketed by Tongji Hospital (see full Tongji Hospital pipeline at /company/tongji-hospital).
What development phase is Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets. in?
Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets. is FDA-approved (marketed).